Cabaletta Bio, INC. (CABA) — 8-K Filings

8-K Filings (21)

• Cabaletta Bio Files 8-K with Exhibits — Apr 20, 2026 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on April 20, 2026, reporting other events and financial statements. The filing includes various exhibits, such as the main 8-K
• Cabaletta Bio Files 8-K Report — Oct 29, 2025 Risk: low
  On October 29, 2025, Cabaletta Bio, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 2929 Arch Street, Su
• Cabaletta Bio Files 8-K Report — Oct 27, 2025 Risk: low
  On October 27, 2025, Cabaletta Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Reg
• Cabaletta Bio, Inc. Files 8-K — Oct 9, 2025 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on October 9, 2025, to report current information. The filing confirms the company's principal executive offices are located at
• 8-K Filing — Sep 3, 2025
• Cabaletta Bio, Inc. Files 8-K: Material Definitive Agreement — Jun 12, 2025 Risk: medium
  On June 11, 2025, Cabaletta Bio, Inc. entered into a Material Definitive Agreement. The filing also includes other events and financial statements and exhibits.
• Cabaletta Bio Terminates Material Definitive Agreement — Jun 11, 2025 Risk: medium
  Cabaletta Bio, Inc. announced on June 11, 2025, the termination of a material definitive agreement. The company, incorporated in Delaware with its principal exe
• Cabaletta Bio Files 8-K on Corporate Actions — Jun 10, 2025 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on June 10, 2025, reporting on events that occurred on June 9, 2025. The filing primarily concerns amendments to its articles o
• Cabaletta Bio Announces Board and Executive Changes — May 19, 2025 Risk: medium
  On May 15, 2025, Cabaletta Bio, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the electi
• Cabaletta Bio Files 8-K for Operations and Financials — Mar 31, 2025 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on March 31, 2025, reporting on its results of operations and financial condition, as well as presenting financial statements a
• Cabaletta Bio Files 8-K Report — Feb 18, 2025 Risk: low
  On February 18, 2025, Cabaletta Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Re
• Cabaletta Bio Files 8-K on Financials and Operations — Jan 13, 2025 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes information relat
• Cabaletta Bio Files 8-K — Nov 18, 2024 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on November 18, 2024, to report on other events and financial statements. The filing does not contain specific details about ne
• Sanofi Acquires Cabaletta Bio for $93M — Oct 7, 2024 Risk: medium
  Cabaletta Bio, Inc. announced on October 7, 2024, that it has entered into a definitive agreement to be acquired by European pharmaceutical company Sanofi for a
• Cabaletta Bio Enters Material Definitive Agreement — Sep 30, 2024 Risk: medium
  On September 30, 2024, Cabaletta Bio, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, its t
• Sanofi to Acquire Cabaletta Bio for $950 Million — Aug 8, 2024 Risk: medium
  Cabaletta Bio, Inc. announced on August 8, 2024, that it has entered into a definitive agreement to be acquired by Sanofi for $9.50 per share in cash, represent
• Cabaletta Bio Acquires Syncona Gene Therapy Portfolio — Jun 14, 2024 Risk: medium
  Cabaletta Bio, Inc. announced on June 14, 2024, that it has entered into a definitive agreement to acquire Syncona Limited's portfolio of gene therapy assets. T
• Cabaletta Bio Reports Shareholder Vote Matters — Jun 4, 2024 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on June 4, 2024, to report on matters submitted to a vote of its security holders. The filing details the submission of specifi
• Cabaletta Bio Files 8-K on Operations and Financials — May 15, 2024 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclos
• Cabaletta Bio, Inc. Files 8-K on Financials — Mar 21, 2024 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on March 21, 2024, reporting on its results of operations and financial condition, and including financial statements and exhib
• Cabaletta Bio Files 8-K — Mar 20, 2024 Risk: low
  Cabaletta Bio, Inc. filed an 8-K on March 20, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain s

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX